Hyperpolarized carbon 13 MRI in liver diseases: Recent advances and future opportunities.

Autor: Ye Z; Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.; The MR Research Center, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Song B; Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan, China., Lee PM; Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, USA., Ohliger MA; Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, USA., Laustsen C; The MR Research Center, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Jazyk: angličtina
Zdroj: Liver international : official journal of the International Association for the Study of the Liver [Liver Int] 2022 May; Vol. 42 (5), pp. 973-983. Date of Electronic Publication: 2022 Mar 12.
DOI: 10.1111/liv.15222
Abstrakt: Hyperpolarized carbon-13 magnetic resonance imaging (HP 13 C MRI) is a recently translated metabolic imaging technique. With dissolution dynamic nuclear polarization (d-DNP), more than 10 000-fold signal enhancement can be readily reached, making it possible to visualize real-time metabolism and specific substrate-to-metabolite conversions in the liver after injecting carbon-13 labelled probes. Increasing evidence suggests that HP 13 C MRI is a potential tool in detecting liver abnormalities, predicting disease progression and monitoring response treatment. In this review, we will introduce the recent progresses of HP 13 C MRI in diffuse liver diseases and liver malignancies and discuss its future opportunities from a clinical perspective, hoping to provide a comprehensive overview of this novel technique in liver diseases and highlight its scientific and clinical potential in the field of hepatology.
(© 2022 The Authors. Liver International published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje